Citi launched a “90-day positive catalyst watch” on Exact Sciences into the Q2 earnings report. The analyst sees “significant upside” to both the company’s Q2 and second half of 2023 numbers as well as the stock’s current valuation. The firm sees “clear conservatism” in Exact’s Q2 guidance and believes positive free cash flow in the quarter implies both revenue and adjusted EBITDA will come in above consensus expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences price target raised to $115 from $92 at Canaccord
- Exact Sciences price target raised to $120 from $85 at Stifel
- Exact Sciences price target raised to $106 from $85 at Craig-Hallum
- Exact Sciences price target raised to $110 from $95 at BTIG
- Exact Sciences price target raised to $130 from $100 at Citi
